The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Pain Res.
Sec. Pharmacological Treatment of Pain
Volume 5 - 2024 |
doi: 10.3389/fpain.2024.1484948
Safety Evaluation of Parenteral Ibuprofen and Ketorolac in Adult and Pediatric Patients
Provisionally accepted
Mosadoluwa Afolabi
1*
Jensy Rodriguez-Silva
1*
Ishveen Chopra
1
Ines Macias-Perez
2
Jason Makii
2*
Emily Durr
2
Theresa Human
2*- 1 STATinMED, LLC, Dallas, TX, United States
- 2 Cumberland Pharmaceuticals (United States), Nashville, United States
The objective of this study was to compare the incidence of adverse drug reactions (ADRs) and healthcare resource utilizations (HCRU) between patients that received intravenous non-steroidal anti-inflammatory drugs (NSAID). This retrospective, longitudinal, observational database study evaluated an all-payer database for patients that received one or more doses of IV-ibuprofen or IV/IM ketorolac between January 1 , 2014 and June 3, 2023. Propensity score matching was applied to both adult (>≥18 yo) and pediatric (<18 yo) population subsets. HCRU was identified within 29 days following the last dose of drug administered. 31,046 IV-ibuprofen and 124,184 ketorolac adults records were identified. 5,579 pediatric patients per arm were identified. Overall ADR incidence was lower and HCRU was lower for adult and pediatric patients who received IV-ibuprofen compared to ketorolac. These results highlight the potential for IV-ibuprofen to improve patient care by offering a safer and more economically favorable option compared to ketorolac, while also enhancing the overall patient experience and reducing the burden on healthcare systems.
Keywords: NSAID, Adverse drug reaction (ADR), Intravenous Ibuprofen, Ketorolac, side effect
Received: 23 Aug 2024; Accepted: 31 Oct 2024.
Copyright: © 2024 Afolabi, Rodriguez-Silva, Chopra, Macias-Perez, Makii, Durr and Human. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mosadoluwa Afolabi, STATinMED, LLC, Dallas, TX, United States
Jensy Rodriguez-Silva, STATinMED, LLC, Dallas, TX, United States
Jason Makii, Cumberland Pharmaceuticals (United States), Nashville, United States
Theresa Human, Cumberland Pharmaceuticals (United States), Nashville, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.